CEACAM6 as a machine learning derived immune biomarker for predicting neoadjuvant chemotherapy response in HR+/HER2- breast cancer.

Front Immunol · 2025 · PMC12420257 · PMID 40936892

Europe PMC DOI

hedged sentence

0.1260

closest p · 2.5× alpha

0.1260

boldest claim

The sentences

a trend toward significanceP = 0.126not close (p > 0.1)

Metastasis status showed a trend toward significance (P = 0.126) Table 2 . 4 Discussion This study aimed to identify molecular prognostic biomarkers associated with neoadjuvant chemotherapy (NAC) response and the immune microenvironment in hormone receptor-positive (HR+)/HER2-negative breast cancer.

also in 3,729 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.